Clinical Trial Update: Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of sorafenib with hydroxychloroquine for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Plaquenil (hydroxychloroquine)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Hepatocellular Cancer | Phase 2 | Status: COMPLETED